Andrew Verderame, MBA, RAC

Area of Expertise:

Andrew Verderame, MBA, RAC

CEO

Andy joined SciLucent as its CEO in 2020 following a successful career in regulatory affairs consulting, where he founded and led the US FDA practice for a global consulting organization.  He has also led high-performing global teams in both start up and multinational pharmaceutical companies.  Andy has considerable experience as a regulatory affairs strategist, developing integrated product development programs and successfully representing companies at FDA pre- and post-submission and Advisory Committee meetings.  Through candor and trust built with FDA, he was the first industry representative ever invited to speak at the Project Manager Staff Forum.  Andy’s specific pharmaceutical expertise includes the development of Cipro and Avelox for infectious diseases; Nexavar for kidney, liver, and thyroid cancer; Gonal-F for fertility treatment; Rebif for multiple sclerosis; and Xarelto for the reduction of stroke.  He is a sought-after speaker on regulatory affairs issues and is a Regulatory Forum leader with MassBio and has chaired sessions at RAPS and DIA annual meetings.  Andy received a Bachelor’s Degree in Chemical Engineering from Clarkson University and an MBA (Pharmaceutical Studies) from Fairleigh Dickinson University.  He maintains Regulatory Affairs Certification (RAC) from RAPS.